Ribbon of Hope: A Collaborative Cancer Support Initiative by BIG Pharmacy and CARiNG Pharmacy

JOHOR BAHRU, Malaysia, Oct. 25, 2024 /PRNewswire/ -- BIG CARiNG Group proudly announces the unveiling of its revolutionary Cancer Support Program, namely "Ribbon of Hope" for you and those you care for at the Biggest Health & Beauty Expo held at Mid Valley Southkey. This initiative is designed to support cancer patients and their caregivers throughout their cancer journey, addressing the growing need for affordable and accessible care for these communities.

Ribbon of Hope Cancer CARE Program: Affordable and Accessible Support  For You and Those You Care

The Ribbon of Hope Cancer CARE Program, a groundbreaking initiative aimed at providing holistic cancer support, is now available at selected BIG Pharmacy and CARiNG Pharmacy locations across Malaysia. This program is designed to be a lifeline of support for both cancer patients and their caregivers, offering crucial resources to aid in their cancer journey.

The Ribbon of Hope Cancer CARE Program is structured around four essential pillars, known as CARE:

Mr Chong Yeow Siang, Managing Director of CARiNG Pharmacy and spokesperson of BIG CARiNG Group, emphasizes, "Our goal with the Ribbon of Hope Cancer CARE Program is to provide a lifeline of support for cancer patients and their families and help navigate patients on their challenges. Through Ribbon of Hope Cancer CARE Program, BIG Pharmacy and CARiNG Pharmacy are committed to offer meaningful, compassionate care and practical resources that meet the unique needs of both patients and caregivers."

Speech by NCSM Representative and MOU Signing with NCSM: A Commitment to Meaningful Collaboration

The launch event saw an impactful speech delivered by Dr Jason Chin Yu Aun, representative of the National Cancer Society of Malaysia (NCSM). He highlighted the importance of collaboration in enhancing public awareness on cancer prevention and screening, as well as the vital role that partnerships like the one between NCSM and BIG CARiNG Group play in improving access to early detection initiatives and supportive care.

Following his speech, the event's highlight unfolded with the signing of a Memorandum of Understanding (MOU) between BIG CARiNG Group and NCSM. This formal collaboration marks a significant step towards increasing cooperation in providing cancer awareness, early detection initiatives, and supportive care across the country.

The MOU was signed by Mr. Lee Meng Chuan, CEO of BIG CARiNG Group; Dr Jason Chin Yu Aun, Medical Officer & Community Health, Operation Lead, CARE Department, Witness by Mr Chong Yeow Siang, Managing Director of CARiNG Pharmacy and Mr. Nik Muhammad Amirul Adli Bin Nik Mohd Sidek, Assistant Coordinator, Guided Patient Support. This official agreement solidifies BIG CARiNG Group's dedication to offering meaningful, compassionate care for cancer patients nationwide.

Health Screening Initiative for Johor Communities

As part of the Health & Beauty Expo, BIG CARiNG Group has partnered with the National Cancer Society of Malaysia(NCSM) to organize a health screening initiative for the Johor communities. The health screening will offer vital services including HPV Vaccinations, Clinical Breast Examinations, Prostate-Specific Antigen Tests, Hepatitis B and Hepatitis C Rapid Antigen Tests, Smokerlyzer Breath Test and doctor's consultation. This initiative underscores BIG CARiNG Group's commitment to early detection and proactive healthcare, ensuring the well-being of the local community through accessible and preventive health services.

Support for Tunku Laksamana Johor Cancer Foundation

In a show of continued support for the cancer community, BIG CARiNG Group also made a generous donation to the Tunku Laksamana Johor Cancer Foundation. The donation included a RM20,000 sponsorship and an additional voucher sponsorship worth RM10,000. Encik Mohd Ikmal Izam Bin Zaini, a representative from the foundation, graciously accepted the contribution during the ceremony.

The successful introduction of the Ribbon of Hope Cancer CARE Program, alongside the health screening initiative, marks an exciting new chapter for BIG CARiNG Group, further cementing its commitment to providing meaningful, compassionate care for cancer patients and their families across Malaysia.

For more information on cancer awareness and support, please visit the National Cancer Society of Malaysia.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Ribbon of Hope: A Collaborative Cancer Support Initiative by BIG Pharmacy and CARiNG Pharmacy

NANJING, China, Oct. 25, 2024 /PRNewswire/ -- On October 24, 2024, TASTE-2, a Chinese innovative stroke drug study led by Professor Wang Yongjun from Beijing Tiantan Hospital, was published in an oral report at the 16^th World Stroke Conference (WSC): brain cell protection combined with edaravone dexborneol (Sanbexin ®) in patients with acute ischemic stroke before endovascular thrombectomy significantly improved the proportion of patients who recovered neurological independence at 90 days and reduced the proportion of patients with disability.

Stroke is the leading cause of death and disability in adults in China, and acute ischemic stroke (AIS) accounts for about 70% of all strokes. Among them, about 40% of patients belong to the risk subtype of large vessel occlusion (LVO), with higher disability and mortality.

After stroke, treatment with "reperfusion", which is represented by thrombolysis and thrombectomy, restores blood supply to the brain as soon as possible. Endovascular thrombectomy (EVT) is an important advance in reperfusion therapy in recent years, which can achieve recanalization in about 70% to 90% of patients with LVO stroke, but only nearly half of patients recover well. A significant proportion of patients with EVT remain disabled to varying degrees after 90 days of treatment.

The oral report on 2024WSC showed that a multicenter, double-blind, randomized, placebo-controlled TASTE-2 study enrolled 1362 patients with moderate-severe stroke treated with EVT. Edaravone dexborneol, a brain cell protection was used before EVT, and the proportion of patients with functional score 2 below 90 days was 55.0% vs. 49.6% compared with placebo, which was statistically significant and safe. This suggests that brain cell protection prior to stroke thrombectomy may further improve treatment outcomes in patients with large vessel occlusive stroke and help them regain self-care ability.

TASTE-2 Primary Efficacy Results: There was a significant difference between the treatment and placebo groups in the proportion of patients who were functionally independent (90-day mRS 0 to 2), OR = 1.24 (1.00 to 1.54), p = 0.047; RR = 1.11 (1.00 to 1.23), p = 0.047

Sanbexin ® (Edaravone dexborneol Concentrated Solution for Injection) is a multi-target brain cell protection developed by Simcere Pharmaceutical Co., Ltd. The drug contains two active ingredients, edaravone and dexborneol, which efficiently penetrate the blood-brain barrier, reduce cascade damage caused by AIS through dual effects of anti-inflammation and free radical scavenging, and extend the existing treatment window from 24 hours to 48 hours. As the only innovative drug approved for marketing and sales in the field of stroke treatment worldwide since 2015, this drug has been developed for 12 years.

The latest results of the TASTE-2 study provide key clinical medical evidence for Sanbexin ® as a multi-target brain cell protection strategy combined with reperfusion in the treatment of acute ischemic stroke and also trigger lively on-site discussion in international academia.

According to the recommendations of the Stroke Academic Roundtable Meeting (STAIR), brain cytoprotectants reduce ischemic brain injury, especially when combined with thrombectomy. The scientific community has also been working on brain cytoprotective agents for stroke treatment for a long time. However, for the complex pathophysiological mechanism of stroke, single-target drugs have limited efficacy and are difficult to develop clinically.

Corresponding to this, multi-target brain cytoprotectants continue to progress in clinical practice. Previously, the TASTE study led by Professor Yongjun Wang 's team from Beijing Tiantan Hospital and the TASTE-SL study led by Professor Dongsheng Fan from Peking University Third Hospital confirmed the efficacy of edaravone dexborneol injection and sublingual tablets in AIS patients without thrombectomy, respectively. The data were published in STROKE (Stroke) and JAMA Neurology (American Medical Association Journal of Neurology), in 2021 and 2024.

In the future, Sanbexin ® is expected to be used as a concomitant drug for endovascular treatment such as thrombectomy and administered before reperfusion to further improve the effect of stroke treatment and reduce stroke disability.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

TASTE-2 World Stroke Congress | Sanbexin ® combined with thrombectomy significantly reduces stroke disability